202 related articles for article (PubMed ID: 37020867)
21. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia.
Timofeeva N; Ayres ML; Baran N; Santiago-O'Farrill JM; Bildik G; Lu Z; Konopleva M; Gandhi V
Front Oncol; 2023; 13():1161254. PubMed ID: 37228498
[TBL] [Abstract][Full Text] [Related]
22. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects.
Tariq S; Tariq S; Khan M; Azhar A; Baig M
Cureus; 2020 Jun; 12(6):e8908. PubMed ID: 32742874
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
26. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
27. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
Thus YJ; Eldering E; Kater AP; Spaargaren M
Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
[TBL] [Abstract][Full Text] [Related]
28. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.
Shen Y; Crassini K; Fatima N; O'Dwyer M; O'Neill M; Christopherson RI; Mulligan SP; Best OG
Blood Adv; 2020 Oct; 4(20):5093-5106. PubMed ID: 33085757
[TBL] [Abstract][Full Text] [Related]
29. The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Schieber M; Ma S
Blood Lymphat Cancer; 2019; 9():9-17. PubMed ID: 32009829
[TBL] [Abstract][Full Text] [Related]
30. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.
Jayappa KD; Gordon VL; Morris CG; Wilson B; Shetty BD; Cios KJ; Arora PC; Isaac KM; Saha S; Bender TP; Williams ME; Portell CA; Weber MJ
Blood Adv; 2021 Sep; 5(17):3497-3510. PubMed ID: 34432864
[TBL] [Abstract][Full Text] [Related]
31. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
32. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Aw A; Brown JR
Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
[TBL] [Abstract][Full Text] [Related]
33. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
35. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
Gong JJ; Yin QS; Li MJ; Ai H; Wang Q; Chen L; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):750-754. PubMed ID: 31648477
[No Abstract] [Full Text] [Related]
36. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
37. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
[TBL] [Abstract][Full Text] [Related]
38. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.
Zhang J; Lu X; Li J; Miao Y
Biomark Res; 2022 Apr; 10(1):17. PubMed ID: 35379357
[TBL] [Abstract][Full Text] [Related]
39. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Gordon MJ; Danilov AV
Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
[TBL] [Abstract][Full Text] [Related]
40. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]